Nervous System News and Research

Latest Nervous System News and Research

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.

9 Dec 2010

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Medulloblastoma subtypes are separate diseases with different origins

International effort led by St. Jude Children's Research Hospital scientists is expected to fuel development of targeted therapies and aid the search for unique combinations of cells and mutations that lead to other cancers.

8 Dec 2010

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study.

8 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

New technique may help develop novel treatments for brain diseases

Scientists have created a way to isolate neural stem cells - cells that give rise to all the cell types of the brain - from human brain tissue with unprecedented precision, an important step toward developing new treatments for conditions of the nervous system, like Parkinson's and Huntington's diseases and spinal cord injury.

8 Dec 2010

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

Alexza Pharmaceuticals, Inc. announced today that the Company has scheduled an End-of Review meeting with the U.S. Food and Drug Administration in December to discuss the Complete Response Letter regarding the Company's New Drug Application for AZ-004 (Staccato loxapine).

8 Dec 2010

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 7 that the available data adequately demonstrate that the potential benefits of Contrave® (naltrexone sustained release (SR)/bupropion SR) outweigh the potential risks when used long-term in a population of overweight and obese individuals and support approval.

8 Dec 2010

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

StemCells, Inc. announced today that is has received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial in Switzerland of the Company's proprietary HuCNS-SC® product candidate (purified human neural stem cells) in chronic spinal cord injury. The trial is designed to assess both safety and preliminary efficacy in patients with varying degrees of paralysis who are three to 12 months post-injury, and will progressively enroll patients based upon the severity of injury.

7 Dec 2010

Restless legs syndrome during pregnancy may reappear later on

Women with transient restless legs syndrome (RLS) during pregnancy appear to be at a higher risk of developing a chronic form of RLS later in life or have the same symptoms during future pregnancies, according to new research published in the December 7, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology. RLS is a sleep-related motor disorder that causes an unpleasant feeling in the legs. The condition generally worsens during rest at night and improves with movement. Symptoms tend to progress with age.

7 Dec 2010

Global phase III study to provide novel extended release of topiramate

Data presented yesterday showed that USL255, a novel extended-release (ER) formulation of topiramate, was associated with less fluctuation in topiramate plasma levels than immediate-release (IR) topiramate in healthy volunteers.

7 Dec 2010

Studies shows that social stress accelerates atherosclerosis development

Studies on genetically engineered mice show that social stress activates the immune system and accelerates the development of atherosclerosis. Commonly used drugs to reduce blood pressure, however, may stop this process. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

7 Dec 2010

Study: Research findings may help identify drugs to encourage myelin repair in MS patients

Damage caused by multiple sclerosis could be reversed by activating stem cells that can repair injury in the central nervous system, a study has shown.

6 Dec 2010

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Today, Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

6 Dec 2010

AANS injury prevention tips during winter holiday season

During the winter holiday season there are many warnings in the news about preventing house fires caused by Christmas trees and faulty electrical wiring. There are also warnings about too much merriment leading to alcohol-related motor vehicle accidents. A lesser known fact is the risk of head injury related to hanging and taking down Christmas decorations.

4 Dec 2010

Closer to restoring vision loss due to optic nerve damage

Damage to the optic nerve, connecting the eye with the brain, is a major cause of blindness. The most common culprit is glaucoma, estimated to affect more than 4 million Americans. There is currently no way to restore the lost vision, because the optic nerve, like other nerves in the mature central nervous system (CNS), cannot regenerate. Now, scientists at Children's Hospital Boston report achieving the greatest regeneration to date in the mammalian optic nerve.

4 Dec 2010

Event reporting prevents medication errors in primary care: Study

The most frequent contributors to medication errors and adverse drug events in busy primary care practice offices are communication problems and lack of knowledge, according to a study of a prototype web-based medication error and adverse drug event reporting system.

4 Dec 2010

China collaborates with Norway to address prevalence and spread of mercury

Highly skilled basic science researchers from China are pooling their talents with analytical environmental researchers from Norway - and their findings are making their mark on Chinese environmental policy.

3 Dec 2010

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

The discovery by UCLA biochemists of a new method for preventing oxidation in the essential fatty acids of cell membranes could lead to a new class of more effective nutritional supplements and potentially help combat neurodegenerative disorders such as Parkinson's disease and perhaps Alzheimer's.

3 Dec 2010

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Zogenix, Inc. and Desitin Pharmaceuticals GmbH today announced that the Danish Medicines Agency of Denmark has approved the Marketing Authorization Application (MAA) for SUMAVEL® DosePro™ (sumatriptan injection) Needle-Free Delivery System. Denmark is the first country in Europe to grant marketing authorization for SUMAVEL DosePro for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache.

2 Dec 2010

Nervous System News and Research

Latest Nervous System News and Research

Euthymics's EB-1010 effective in treatment of major depressive disorder: Study

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Medulloblastoma subtypes are separate diseases with different origins

Cipher Phase 3 dermatology study uses MedAvante Centralized Ratings

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

New technique may help develop novel treatments for brain diseases

Alexza Pharmaceuticals to meet with FDA to discuss CRL regarding its NDA for AZ-004

FDA Advisory Committee votes in favor of Orexigen's Contrave for treatment of obesity

StemCells receives Swissmedic authorization to initiate HuCNS-SC Phase I/II clinical trial in spinal cord injury

Restless legs syndrome during pregnancy may reappear later on

Global phase III study to provide novel extended release of topiramate

Studies shows that social stress accelerates atherosclerosis development

Study: Research findings may help identify drugs to encourage myelin repair in MS patients

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

AANS injury prevention tips during winter holiday season

Closer to restoring vision loss due to optic nerve damage

Event reporting prevents medication errors in primary care: Study

China collaborates with Norway to address prevalence and spread of mercury

UCLA findings could lead to enhanced health supplements, progress on Parkinson's

Denmark grants marketing authorization for SUMAVEL DosePro Needle-Free Delivery System

Industry Focus eBook - Medical device (1st edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Nervous System News and Research

Latest Nervous System News and Research

Industry Focus eBook - Medical device (1st edition) eBook

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Newsletters you may be interested in